Session date: 
Wednesday, December 26, 2018 - 8:00am to 9:00am
Location: 
Medical College of Wisconsin, Department of Pathology Administration
WDL Building, 9200 W Wisconsin Avenue
Room 230
Milwaukee, WI 53226
United States
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.
Program Description: 

This educational activity is based on case presentations and subsequent small group discussions of patients with hematologic malignancies that are being evaluated, treated and followed in the Department of Hematology and Oncology, and that have diagnostic or follow-up material evaluated in the Division of Hematopathology.  The goal of this multimodality approach is to insure that the best patient care is being delivered by both Hematologists/Oncologists and Pathologists.

ACCME Accreditation Statement:

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement:

The Medical College of Wisconsin designates this Live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of  Participation for Allied Health Professionals

The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Target audience: 
Hematologist
Oncologist
Hematopathologist
Learning objectives: 

Learning objectives are identified for both Hematologists/Oncologists and Hematopathologists.

By completing this activity, Hematologists/Oncologists will be able to:

  1. Improve their ability to appropriately order expensive ancillary diagnostic tests.
  2. Recognize the salient morphologic, immunophenotypic, cytogenetic and molecular features of common hematologic malignancies.

By completing this activity, Hematopathologists will be able to:

  1. Discuss emergent therapeutic options and availability of clinical trials, and how they apply to patients diagnosed in our service.
  2. Utilize and constantly update themselves with the clinical practices of the Department of Hematology and Oncology, in order to continue to improve outcomes and provide optimal patient care.
Faculty & credentials: 

Planning Committee:

Horatiu Olteanu, MD, PhD
Associate Professor of Pathology

Ehab Atallah, MD
Associate Professor of Medicine

Laura Michaelis, MD
Associate Professor of Medicine

Steven Kroft, MD
Associate Professor of Medicine
 
Alexandra Harrington, MD
Associate Professor of Medicine

All persons in control of content have NO relevant financial relationships to disclosure.

NameCompanyRole
Laura Michaelis, MDIncyte, Celgene, NovartisAdvisory Board, Speaker

In accordance with the ACCME® standard for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.

CME Coordinator Contact Information

Name: 
Shannon Majewski
Phone number: 
+1 (414) 805-6976